Newsletter | April 9, 2024

04.09.24 -- PROTACs And Molecular Glues: Rethinking What Is Possible

FEATURED EDITORIAL

PROTACs And Molecular Glues: Rethinking What Is Possible

This article explores the potential of novel small molecule approaches to address undruggable targets in oncology, including PROteolysis TArgeting Chimeras (PROTACs) and molecular glues, and how they work. 

INDUSTRY INSIGHTS

Talent And Supply: Building A Foundation For The Future Of Biopharma

Read how to create future-ready facilities supported by advanced scientific knowledge and a secure supply chain that can handle the unprecedented demands and constraints of a post-COVID world.

Trends In Next-Generation Delivery Technologies

Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.

Reducing Wastewater Incineration And Carbon Emissions

To reduce CO2 emissions and recycle higher volumes of solvent, manufacturers must engineer approaches with flexible technologies that can be adapted to accommodate different products.

Post-Pandemic Outsourcing Demand: How Are CDMOs Responding?

Ultimately, to serve the highly competitive biopharma and pharmaceutical markets, CDMOs must be adaptable to the culture of the company for whom they are working.

Using Nanotechnology To Increase Drug Development Efficiency

Many complex molecules progressing through development exhibit solubility and bioavailability challenges. Discover how nanoforming drug particles to below 100 nm could help.

Solid Form Screening, Rapid Formulation Selection To Meet Tight Timelines

A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

SOLUTIONS

Protein L Resin For Affinity Capture

Custom Organ-Chip Models For Various Applications